A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Carvedilol (Primary)
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Chong Kun Dang
- 18 Sep 2019 Last checked against Korean Clinical Trials Register record.
- 13 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Feb 2013 Planned end date changed from 1 Aug 2013 to 2 Sep 2013 as reported by Korean Clinical Trials Register.